UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On March 21, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated March 21, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| United-Guardian, Inc. | ||
| Date: March 21, 2025 | By: | /s/ Donna Vigilante |
| Donna Vigilante | ||
| President | ||
EXHIBIT 99.1
United-Guardian Reports 2024 Financial Results
HAUPPAUGE, N.Y., March 21, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2024 increased compared to FY 2023. Net sales for the year increased by 12% from $10,885,154 in 2023 to $12,181,971 in 2024, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,581,370 ($0.56 per share) in 2023.
Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that net sales and net income increased from 2023 to 2024. Sales of cosmetics ingredients and medical lubricants increased by 32% and 16%, respectively. The increase in cosmetic ingredient sales was primarily due to increased purchase orders from our largest distributor. Based on feedback from our distributor, the increase was due to greater demand for our products in China as a result of regaining market share at certain key accounts. The increase in medical lubricants was driven by greater demand from one of our large contract manufacturer customers in China. Pharmaceutical sales decreased by 5% in 2024, due to a supply disruption of Renacidin, our main pharmaceutical product, that we experienced at the end of 2023 and carried into the first quarter of 2024. This disruption impacted our sales of Renacidin for 2024. Sales began increasing once supply levels resumed, and we are hopeful that sales of Renacidin will return to their previous levels in 2025.”
United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants.
| Contact: | Donna Vigilante |
| (631) 273-0900 | |
| [email protected] |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 STATEMENTS OF INCOME | ||||||||
| Years ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Net sales | $ | 12,181,971 | $ | 10,885,154 | ||||
| Costs and expenses: | ||||||||
| Cost of sales | 5,721,584 | 5,479,566 | ||||||
| Operating expenses | 2,356,819 | 2,078,564 | ||||||
| Research and development | 456,779 | 463,992 | ||||||
| Total costs and expenses | 8,535,182 | 8,022,122 | ||||||
| Income from operations | 3,646,789 | 2,863,032 | ||||||
| Other income: | ||||||||
| Investment income | 434,679 | 306,651 | ||||||
| Net gain on marketable securities | 26,989 | 81,095 | ||||||
| Total other income | 461,668 | 387,746 | ||||||
| Income before provision for income taxes | 4,108,457 | 3,250,778 | ||||||
| Provision for income taxes | 857,582 | 669,408 | ||||||
| Net income | $ | 3,250,875 | $ | 2,581,370 | ||||
| Earnings per common share (basic and diluted) | $ | 0.71 | $ | 0.56 | ||||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||||
| BALANCE SHEET DATA (condensed) | |||||||
| December 31, | |||||||
| 2024 | 2023 | ||||||
| Current assets: | $ | 12,665,551 | $ | 12,252,713 | |||
| Deferred income taxes, net | 175,397 | 50,930 | |||||
| Property, plant, and equipment, net | 956,387 | 619,195 | |||||
| Total assets | 13,797,335 | 12,922,838 | |||||
| Current liabilities: | 1,914,469 | 1,534,256 | |||||
| Total liabilities | 1,914,469 | 1,534,256 | |||||
| Stockholders’ equity | 11,882,866 | 11,388,582 | |||||
Total liabilities and stockholders’ equity | $ | 13,797,335 | $ | 12,922,838 | |||